

# Montana Healthcare Programs Drug Utilization Review Board Agenda

Hosted by Mountain Pacific Quality Health

November 9, 2022

1-4 PM

Virtual Call Only

Register in advance for this meeting:

<https://mpqhf.zoom.us/meeting/register/tJ0oc-yhpzvwGNZdnByq3ixhj-nhtxV2RNwS>

## 1. Introductions

## 2. Public Comment- 15 minutes

All persons wishing to speak through the video conferencing platform must notify the Department by submitting their name and topic they wish to speak on via <https://forms.office.com/g/EkPyKbJYTv> by **noon** the day prior to the meeting. Individual comment will be limited to a maximum of 3 minutes per person and is subject to further limitations depending on the number of speakers (15 minutes divided by total speakers).

Due to time constraints, all persons are encouraged to provide written comment, especially those providing clinical information, to allow the board adequate time to review and research. Please email written comments and/or clinical information, with a statement indicating that it is public comment, to [PDL@mt.gov](mailto:PDL@mt.gov) at least 7 days prior to the meeting. Please limit clinical information to 2 pages and to new information since last review. New peer-reviewed randomized comparative controlled trials or randomized controlled trials with true health outcomes are most helpful. Please do not provide any pricing information.

## 3. Meeting Minutes

## 4. Department Update

## 5. Criteria Discussion

- Criteria for new drugs
  - Auvelity®
  - Hyftor®
  - Sotyktu®
  - Ztalmy®
- Discussion on Kloxxado® place in therapy -request from May 2022 PDL meeting
- Criteria and PA form update

- Cystic Fibrosis medications
  - Orkambi® new indication (now indicated down to 1 year old)
  - Address all CF medication to make criteria and forms consistent
- Dupixent® new indication
- Interleukin antagonists
  - Skyrizi® new indications and criteria sheet update for PA and PAD consistency
  - Update criteria sheets for PA and PAD consistency
    - Stelara®
    - Tremfya®
    - Ilumya®
- Update of Austedo® criteria sheets
- Preferred Drug List trial discussion-no additional criteria added
  - Trial requirements in classes not grouped by MOA, such as Novel Antidepressants
  - Trial requirements in PDL classes with combination drugs, such as Ryaltris®, COPD inhalers, etc.
  - Trial requirements for alternative dosage forms, such as Tadliq® and others

6. Criteria Removal

7. Update to the Board on Gabapentin/Lyrica Limit Implementation

8. Atypical Antipsychotics in Children Criteria Discussion

9. Meeting Date Discussion for 2023

- PDL meetings for 2023: March 15, April 26, May 24
- January 25, June 28 OR July 26, September 27, October 25 OR November 8